Published in J Exp Med on February 07, 2005
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) (2009) 1.51
Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis. Crit Care Med (2010) 1.47
Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care (2008) 1.34
Prolonged treatment with N-acetylcystine delays liver recovery from acetaminophen hepatotoxicity. Crit Care (2009) 1.32
Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med (2009) 1.25
Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol (2010) 1.22
RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways. PLoS One (2010) 1.15
Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med (2007) 1.14
Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology (2009) 1.07
RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol (2010) 1.07
Carbon monoxide enhances early liver regeneration in mice after hepatectomy. Hepatology (2011) 0.94
The role of receptor for advanced glycation endproducts (RAGE) in infection. Crit Care (2011) 0.92
Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology (2013) 0.90
RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. Diabetes (2012) 0.89
High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity. BMC Gastroenterol (2012) 0.89
Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology. PLoS One (2014) 0.89
Opposing roles of RAGE and Myd88 signaling in extensive liver resection. FASEB J (2011) 0.89
Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol (2009) 0.88
Ringer's lactate improves liver recovery in a murine model of acetaminophen toxicity. BMC Gastroenterol (2011) 0.85
Tanshinone IIA protects rabbits against LPS-induced disseminated intravascular coagulation (DIC). Acta Pharmacol Sin (2012) 0.82
The NF-κB subunit RelA/p65 is dispensable for successful liver regeneration after partial hepatectomy in mice. PLoS One (2012) 0.82
IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med Chem (2013) 0.81
Ethyl pyruvate reduces liver injury at early phase but impairs regeneration at late phase in acetaminophen overdose. Crit Care (2012) 0.81
Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol (2014) 0.79
Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. J Pharmacol Exp Ther (2014) 0.79
Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol (2015) 0.78
Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma. Eur J Nucl Med Mol Imaging (2007) 0.78
Role of receptor for advanced glycation end products (RAGE) in liver disease. Eur J Med Res (2015) 0.78
Matrix metalloproteinase-9 in the initial injury after hepatectomy in mice. World J Gastroenterol (2013) 0.77
Improved prescription of taohechengqi-tang alleviates D-galactosamine acute liver failure in rats. World J Gastroenterol (2016) 0.75
Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice. Front Cell Neurosci (2016) 0.75
Follicular fluid soluble receptor for advanced glycation endproducts (sRAGE): a potential protective role in polycystic ovary syndrome. J Assist Reprod Genet (2016) 0.75
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem (2017) 0.75
HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 17.72
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
Liver regeneration. Science (1997) 12.80
Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 12.23
Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature (1995) 10.36
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med (2000) 7.38
Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science (1996) 6.70
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol (1999) 5.98
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
Liver regeneration. J Hepatol (2000) 5.22
Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A (1997) 4.33
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem (1999) 3.12
The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol (1995) 2.67
IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J Immunol (1994) 1.96
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology (2004) 1.77
Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology (1999) 1.64
Rapid activation of post-hepatectomy factor/nuclear factor kappa B in hepatocytes, a primary response in the regenerating liver. J Biol Chem (1994) 1.64
Tumor necrosis factor primes hepatocytes for DNA replication in the rat. Hepatology (1998) 1.60
Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J Clin Invest (2002) 1.58
Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol (2004) 1.55
Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations. J Immunol (2003) 1.53
Functional analysis of grafts from living donors. Implications for the treatment of older recipients. Ann Surg (1996) 1.51
Combinatorial interactions between AP-1 and ets domain proteins contribute to the developmental regulation of the macrophage scavenger receptor gene. Mol Cell Biol (1994) 1.49
RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J (2004) 1.35
Progressive necrosis after hepatectomy and the pathophysiology of liver failure after massive resection. Surgery (1997) 1.33
Cyclin D1 promotes mitogen-independent cell cycle progression in hepatocytes. Cell Growth Differ (1999) 1.29
Dendritic cells and immune regulation in the liver. Gut (2003) 1.19
Induction of early-immediate genes by tumor necrosis factor alpha contribute to liver repair following chemical-induced hepatotoxicity. Hepatology (1997) 1.19
Modifications of the hepatocyte growth factor/c-met pathway by constitutive expression of transforming growth factor-alpha in rat liver epithelial cells. Mol Carcinog (1997) 0.97
Kupffer cell-mediated recruitment of dendritic cells to the liver crucial for a host defense. Dev Immunol (2002) 0.94
Normal pharmacologically-induced, but decreased regenerative liver growth in interleukin-6-deficient (IL-6(-/-)) mice. J Hepatol (2000) 0.84
Roles of growth factors and of tumor necrosis factor-alpha on liver cell proliferation induced in rats by lead nitrate. Lab Invest (1994) 0.82
Small-for-size liver transplanted into larger recipient: a model of hepatic regeneration. Hepatology (1994) 0.79
Cell adhesion molecules activate signaling networks that influence proliferation, gene expression, and differentiation. Ann N Y Acad Sci (2002) 0.78
DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature (2007) 13.56
Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation (2006) 5.31
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res (2004) 4.00
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 3.93
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 3.86
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med (2009) 3.70
Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol (2006) 3.42
Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology (2014) 3.29
Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci U S A (2008) 3.27
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol (2006) 3.03
Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg (2009) 2.95
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology (2005) 2.74
Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood (2003) 2.73
Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg (2005) 2.64
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain (2010) 2.41
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res (2003) 2.25
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res (2010) 2.19
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2003) 2.17
Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst (2008) 2.15
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation (2003) 2.14
Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab (2008) 2.13
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood (2009) 2.06
S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem (2003) 2.05
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
Identification, classification, and expression of RAGE gene splice variants. FASEB J (2007) 1.96
Impaired tRNA nuclear export links DNA damage and cell-cycle checkpoint. Cell (2007) 1.94
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res (2008) 1.94
Managing the prevention of retained surgical instruments: what is the value of counting? Ann Surg (2008) 1.92
Donor morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.90
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90
DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale. Nucleic Acids Res (2013) 1.86
Urinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation. Nephrol Dial Transplant (2011) 1.86
Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis (2012) 1.84
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts. J Leukoc Biol (2009) 1.84
Integrating gene and protein expression data: pattern analysis and profile mining. Methods (2005) 1.83
Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res (2009) 1.83
A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res (2007) 1.80
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology (2004) 1.77
Candidate lung tumor susceptibility genes identified through whole-genome association analyses in inbred mice. Nat Genet (2006) 1.77
Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J Exp Med (2013) 1.77
Protein glycation: a firm link to endothelial cell dysfunction. Circ Res (2004) 1.76
Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology (2006) 1.75
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells. Eur J Immunol (2007) 1.70
Choroidal neovascularization after epiretinal membrane removal. Arch Ophthalmol (2006) 1.70
RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis (2005) 1.67
Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci (2008) 1.67
Multiplex PCR assay for identification of human diarrheagenic Escherichia coli. J Clin Microbiol (2003) 1.66
Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J Clin Invest (2014) 1.66
The mitochondrial pathway of anesthetic isoflurane-induced apoptosis. J Biol Chem (2009) 1.64